You should be ashamed of yourself, Dew! Actually... I wish I had thought of that.

Nice. The rules say you have to pick at least 8, but you only wanted 6. Clever.

For anyone keeping an eye on ASH 2019, I've created a spreadsheet of participating BioPharma companies available at the link below. Feel free to suggest additions/deletions as it's very unlikely that I've captured all of them. If anyone knows of a master list of ticker symbols that's already been assembled, please share.

Spreadsheet of BioPharma Companies at ASH 2019

No worries. I'd rather list them just to have them on my radar.

Got it. Thank you.

Thanks. I don't think that ALKS has formally stated what the plan for 5461 is, so I'll add it to the list.

Thanks, Ian (and Xavier). It's just a three-name list at this point. Feel free to send more tickers if they come to mind and I'll add them to the list.

Depression

Sure. Given what's going on with SAGE this morning I wish that I had a list of companies competing in depression. If anyone has a list of tickers, please share and I'll create a spreadsheet.

The buyout of BOLD seems to have given a boost to several of the gene therapy companies. Here's a link to my GT spreadsheet if you'd like to compare at a high level.

Gene Therapy Spreadsheet

I poked around a bit in search of the source too. No luck yet.

Bloomberg note regarding FGEN/AZN

Maybe this data is really, really good.

From an Aug 12 press release:

Second Quarter Highlights and Recent Developments

Remained on schedule to report top line data in Q3 2019 for AR-105's global Phase 2 clinical trial for the treatment of ventilator-associated pneumonia (VAP) caused by Pseudomonas aeruginosa (P. aeruginosa).

That was a nosedive yesterday. High volume too. I'm assuming that the CC didn't go well. I'll read the transcript this weekend.

That's down from 12.2% though. See the SC 13D/A from about a year ago.

Never mind. I see that they filed their Q3 13F-HR late yesterday.

Where did you find that information? Link please? Thx.

Information about AFMD's ASH presentations has been out for a week.

Affimed to Present Preclinical Data on Bi- and Trispecific Immune Cell Engagers at ASH

AFM13 Is the Most Advanced Bispecific NK-Cell Engaging Antibody in Clinical Development Substantially Enhancing NK-Cell Effector Function and Proliferation (Abstract #1764)
Session: 622. Lymphoma Biology - Non-Genetic Studies: Poster I
Date: Saturday, December 3, 2016: 5:30-7:30 p.m. (PT)
Location: Hall GH (San Diego Convention Center)
 
Functional Defects of T Cells of NHL Patients after Different Chemotherapy Regimens Activated By CD19/CD3 Tetravalent Bispecific TandAb® AFM11 (Abstract #4130)
Session: 622. Lymphoma Biology - Non-Genetic Studies: Poster III
Date: Monday, December 5, 2016: 6:00-8:00 p.m. Pacific Time
Location: Hall GH (San Diego Convention Center)
 
Trispecific Antibodies for Selective CD16A-Directed NK-Cell Engagement in Multiple Myeloma (Abstract #4513)
Session: 653. Myeloma: Therapy, excluding Transplantation: Poster III
Date: Monday, December 5, 2016: 6:00-8:00 p.m. Pacific Time
Location: Hall GH (San Diego Convention Center)

Maybe updates regarding AFM13 progress will be shared soon (and they're favorable). From their Q3 PR:

Affimed’s Phase 1b combination study of AFM13, a CD30/CD16A TandAb, with Keytruda® (pembrolizumab) in Hodgkin lymphoma (HL) is ongoing and now recruiting into the second dose cohort. The Company intends to provide a first update on the study by the end of 2016 or first quarter of 2017.

In the Phase 2a monotherapy trial for AFM13 in HL sponsored by the German Hodgkin Study Group (GHSG), Affimed is working with the sponsor to revise the study protocol, and anticipates providing an update on the revised in- and exclusion criteria and overall study design by the end of 2016. The study remains open and recruiting under the original study protocol to gain insights into specific patient subsets.

http://www.affimed.com/pdf/20161102_affimed_pr_3q16_final.pdf

Per an 8-K filed this morning:

On October 17, 2016, James M. Roach, M.D., informed Momenta Pharmaceuticals, Inc. (the “Company”) of his intention to resign from his roles as the Company's Senior Vice President, Development and Chief Medical Officer, effective on or around November 29, 2016.

PTLA / Deerfield SC 13G
PTLA tanked on bad news on 3/23. According to a Form SC 13G filing that became available on sec.gov today, Deerfield Management owned 5.48% of the PTLA shares as of 3/24/2016 (3,089,785 shares). And going back to Deerfield's most recent 13F-HR filing (12/31), they only owned 683,749 shares. I wonder if they bought the difference on 3/24 (after the 30% nose dive). Hopefully the folks at Deerfield have done their homework. FWIW... I don't follow PTLA.

Good catch. I scrolled right down to the summary table. The RSS feed definitely indicates that the filing date is today.

<filing-date>2016-03-30</filing-date>

I see that Teva filed a Form SC 13G with the SEC indicating that it has acquired 7.7% of Xenon Pharmaceuticals shares (XENE).

SC 13G

I'll go out on a limb and guess that the number of shares you currently own is roughly one-sixth of the number that you purchased.

Never mind.

The BV board is actually quite good, in my opinion. Very sharp contributors for the most part. On occasion, someone might get 'attacked'... but usually their position is politely challenged first. If they continue to rattle on incoherently or break out the pom-poms, they should definitely expect to be 'attacked'. When I have time to browse ihub, my first stop is usually the BV board.

OT: Dorin... this issue has very little to do with BQI or how many shares of the stock you own. Re-posting drivel from another website or 'fellow bigbri' does not qualify as 'due diligence'. If you don't like people calling you on this nonsense, don't post it. Unfortunately, the 'Ignore This Member' feature on this website doesn't work for me.

OT:
Chuckle. Here's another BQI-related 'hot tip' from Dorin (aka DFRAI).

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=64506387

Hey... he might be right... but I'd rather play Lotto.

I haven't watched the 60 Minutes piece yet, but I see that GreenTech summarized it here on 2/22/2010.

http://techcrunch.com/2010/02/22/bloom-energy-boxes/

This quote from the GreenTech article makes me question the availability of the smaller, $3K box you're referring to.

My recollection is that a 'Bloom Box' costs about $500K. And you need two of them to provide enough power for an average house.

That's exactly the response I expected from you. At least you're consistent.

If you're going to be condescending, at least learn how to spell.
'Kindergarden'?

TD Ameritrade won't allow me purchase RGDX online. Apparently I'll have to place the order over the phone. With two TDA accounts totaling well into seven figures, and no purchases on margin, you'd think that they'd cut me some slack.

Why are you guessing this? Curious.

Why?

The last time I looked, ARNA was a one-trick pony... and that pony was on its last leg. That wouldn't stop Lief from saying otherwise though.

Sounds like Jack Lief of ARNA, but that's just a WAG.

It could be due to a rumor posted at TheFlyOnTheWall.com:
"Momenta Pharma moves up on renewed takeover chatter"

It looks like the 'Authorized Indian Agent' for bringing ITALFARMACO's enox into India is 'M/s. ESSCHEM PVT. LTD., MUMBAI'. I found a table labeled 'RENEWAL REGISTRAION - LIST OF FINISHED FORMULATION-2008' with an entry that shows this association. There were a few more instances of this on other pages at their website as well. The details you're looking for aren't provided, but I thought that I'd share this anyway. See...

http://cdsco.nic.in/HTML/RENEWAL%20REGISTRATION%20bd&FF.htm

Well.... at the current price of $1.63 you're definitely not 'sitting on a gain' for the 1450 shares that you bought at $1.97. This stock won't see $2.00 again anytime soon, if ever.

I'd sell it all in the morning and cut your losses.